HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Greyson to make radio debut

This article was originally published in The Rose Sheet

Executive Summary

Beauty researcher and marketer has partnered with media conglomerate Clear Channel Communications to introduce its skin-care treatment line on two Florida-based radio stations, firm says July 25. Slated to broadcast Sept. 6 on 1290 WJNO and 1230 WBZT, the program will feature Greyson CEO and President Harvey Tauman talking about topics in health and wellness and fielding questions from listeners about Greyson products. Listeners will be directed to the company's Web site to purchase products. "We are confident that our marketing strategy, complemented by a rigorous on-air and online advertising platform, will effectively introduce the Greyson product line to millions of potential customers across the country," says Tauman. Firm also will become exclusive sponsor of the Randi Rhodes Personality Page on WJNO.com. Greyson makes and markets Aspirations by Jennifer Greyson line of anti-aging skin care...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel